HLA-E as an Emerging Checkpoint and Biomarker in Personalized Cancer Immunotherapy

Abstract

Human leukocyte antigen (HLA) molecules play a predominant role in cancer immunotherapy by harnessing the immune system’s capacity to differentiate between healthy and malignant cells. Most human cell types express HLA class I molecules, which interact with T-cell receptors (TCRs) to activate T cells and initiate adaptive immunological responses. The efficacy of several immunotherapeutic strategies, including checkpoint inhibitors, CAR-T-cell therapy, and personalized cancer vaccines, is significantly influenced by HLA diversity and polymorphisms. Human leukocyte antigen E (HLA-E) is a non-classical major histocompatibility complex class I (MHC-I) protein that plays a crucial role in immune regulation. Unlike classical HLA molecules, HLA-E exhibits unique immunosuppressive properties that influence tumor immune evasion mechanisms. Recent studies have highlighted the importance of HLA-E expression in various hematological malignancies and solid tumors. HLA-E interacts with inhibitory receptors on natural killer (NK) cells and certain T-cell subsets, thereby modulating immune responses against tumor cells. The expression of HLA-E on tumor cells can lead to immune escape by inhibiting the cytotoxic activity of NK and CD8+ T cells, which are critical for effective anti-tumor immunity. This review summarizes how HLA-E presents antigens, discusses recent advances in identifying HLA-E-restricted peptides, and evaluates current HLA-E-dependent and HLA-E-independent adoptive immunotherapies. Understanding the role of HLA-E in tumor immune evasion provides valuable insights for developing novel personalized cancer immunotherapies. Targeting HLA-E has the potential to increase the effectiveness of current treatments and improve patient prognosis across diverse cancer types.

Keywords

HLA-E / NKG2A / Cancer immunotherapy / Biomarkers / Immunocheckpoint inhibitors / Personalized medicine / Tumor immune evasion

References

[1] Szeto GL, Finley SD. Integrative approaches to cancer immunotherapy. Trends Cancer.. 2019, 5(7): 400-410.

[2] Riley RS, June CH, Langer Ret al. . Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov.. 2019, 18(3): 175-196.

[3] Sung H, Ferlay J, Siegel RLet al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.. 2021, 71(3): 209-249

[4] Wang Y, Wang M, Wu HXet al. . Advancing to the era of cancer immunotherapy. Cancer Commun.. 2021, 41(9): 803-829.

[5] Bandara S, Raveendran S. Current landscape and future directions in cancer immunotherapy: therapies, trials, and challenges. Cancers.. 2025, 17(5): 821.

[6] Li H, Han S, Dong Cet al. . Advancements in conventional cancer therapy combined with immunotherapy. Oncol Transl Med.. 2025, 11117-28.

[7] Kim J, Maharjan R, Park J. Current trends and innovative approaches in cancer immunotherapy. AAPS PharmSciTech.. 2024, 25(6): 168.

[8] Tang L, Huang Z, Mei Het al. . Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduct Target Ther.. 2023, 81306.

[9] Liu B, Zhou H, Tan Let al. . Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther.. 2024, 9: 175.

[10] Kiyotani K, Toyoshima Y, Nakamura Y. Personalized immunotherapy in cancer precision medicine. Cancer Biol Med.. 2021, 184955-965

[11] Sankar K, Ye JC, Li Zet al. . The role of biomarkers in personalized immunotherapy. Biomark Res.. 2022, 10132.

[12] Holtsträter C, Schrörs B, Bukur T, et al. Bioinformatics for cancer immunotherapy. Bioinformatics for Cancer Immunotherapy. New York, NY: Springer US,; 2020:1–9.

[13] Jain KK. Personalized immuno-oncology. Textbook of Personalized Medicine. Cham: Springer International Publishing,; 2020:479–508.

[14] Dyikanov D, Zaitsev A, Vasileva Tet al. . Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer. Cancer Cell.. 2024, 425759-779.e12.

[15] Botticelli A, Pomati G, Cirillo Aet al. . The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy. Front Immunol.. 2022, 13. 974087

[16] Schaafsma E, Fugle CM, Wang Xet al. . Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy. Br J Cancer.. 2021, 125(3): 422-432.

[17] Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer.. 2021, 21(5): 298-312.

[18] Pishesha N, Harmand TJ, Ploegh HL. A guide to antigen processing and presentation. Nat Rev Immunol.. 2022, 22(12): 751-764.

[19] Bukur J, Jasinski S, Seliger B. The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol.. 2012, 22(4): 350-358.

[20] Benitez Fuentes JD, Bartolome Arcilla J, Mohamed Mohamed Ket al. . Targeting of non-classical human leukocyte antigens as novel therapeutic strategies in cancer. Cancers.. 2024, 16(24): 4266.

[21] Gillespie GM, Quastel MN, McMichael AJ. HLA-E: immune receptor functional mechanisms revealed by structural studies. Immunol Rev.. 2025, 3291. e13434

[22] Bartolome J, Molto C, Benitez-Fuentes JDet al. . Prognostic value of human leukocyte antigen G expression in solid tumors: a systematic review and meta-analysis. Front Immunol.. 2023, 14: 1165813.

[23] Benitez Fuentes JD, Bartolome Arcilla J, Lazaro Sanchez ADet al. . Association between human leukocyte antigen E expression and outcomes in solid tumors: a systematic review and meta-analysis. Front Oncol.. 2025, 151525924.

[24] Kyrysyuk O, Wucherpfennig KW. Designing cancer immunotherapies that engage T cells and NK cells. Annu Rev Immunol.. 2023, 4117-38.

[25] Kulski JK, Suzuki S, Shiina T. Human leukocyte antigen super-locus: nexus of genomic supergenes, SNPs, indels, transcripts, and haplotypes. Hum Genome Var.. 2022, 9149.

[26] Kraemer T, Blasczyk R, Bade-Doeding C. HLA-E: a novel player for histocompatibility. J Immunol Res.. 2014, 20141352160

[27] Celik AA, Kraemer T, Huyton Tet al. . The diversity of the HLA-E-restricted peptide repertoire explains the immunological impact of the Arg107Gly mismatch. Immunogenetics.. 2016, 68129-41.

[28] Kanevskiy L, Erokhina S, Kobyzeva Pet al. . Dimorphism of HLA-E and its disease association. Int J Mol Sci.. 2019, 20(21): 5496.

[29] Grimsley C, Ober C. Population genetic studies of HLA-E: evidence for selection. Hum Immunol.. 1997, 52133-40.

[30] Weitzen M, Shahbazy M, Kapoor Set al. . Deciphering the HLA-E immunopeptidome with mass spectrometry: an opportunity for universal mRNA vaccines and T-cell-directed immunotherapies. Front Immunol.. 2024, 15: 1442783.

[31] Walters LC, Rozbesky D, Harlos Ket al. . Primary and secondary functions of HLA-E are determined by stability and conformation of the peptide-bound complexes. Cell Rep.. 2022, 39(11. 110959

[32] Lee N, Llano M, Carretero Met al. . HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A.. 1998, 959): 5199-5204.

[33] O’Callaghan CA, Tormo J, Willcox BEet al. . Structural features impose tight peptide binding specificity in the nonclassical MHC molecule HLA-E. Mol Cell.. 1998, 14531-541.

[34] Braud VM, Allan DSJ, O’Callaghan CAet al. . HLA-E binds to natural killer cell receptors CD94/NKG2A. B and C. Nature.. 1998, 391(6669): 795-799

[35] Borrego F, Ulbrecht M, Weiss EHet al. . Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence–derived peptides by CD94/NKG2 confers protection from natural killer cell–mediated lysis. J Exp Med.. 1998, 187(5): 813-818.

[36] He W, Gea-Mallorquí E, Colin-York Het al. . Intracellular trafficking of HLA-E and its regulation. J Exp Med.. 2023, 220(8. e20221941

[37] Borst L, van der Burg SH, van Hall T. The NKG2A–HLA-E axis as a novel checkpoint in the tumor microenvironment. Clin Cancer Res.. 2020, 2621): 5549-5556.

[38] Valés-Gómez M, Reyburn HT, Erskine RAet al. . Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J.. 1999, 18(15): 4250-4260.

[39] Pérez-Villar JJ, Melero I, Navarro Fet al. . The CD94/NKG2-a inhibitory receptor complex is involved in natural killer cell-mediated recognition of cells expressing HLA-G1. J Immunol.. 1997, 158(12): 5736-5743.

[40] Llano M, Lee N, Navarro Fet al. . HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol.. 1998, 28(9): 2854-2863.

[41] Wagner B, da Silva Nardi F, Schramm Set al. . HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia. Cancer.. 2017, 123(5): 814-823.

[42] Zheng H, Lu R, Xie Set al. . Human leukocyte antigen-E alleles and expression in patients with serous ovarian cancer. Cancer Sci.. 2015, 106(5): 522-528.

[43] Xu YP, Wieten L, Wang SXet al. . Clinical significance of HLA-E genotype and surface/soluble expression levels between healthy individuals and patients with acute leukemia. Leuk Lymphoma.. 2019, 60(1): 208-215.

[44] Hirankarn N, Kimkong I, Mutirangura A. HLA-E polymorphism in patients with nasopharyngeal carcinoma. Tissue Antigens.. 2004, 64(5): 588-592.

[45] Douik H, Romdhane NA, Guemira F. Are HLA-E*0103 alleles predictive markers for nasopharyngeal cancer risk?. Pathol Res Pract.. 2016, 212(4): 345-349.

[46] Martín P, Krsnik I, Navarro Bet al. . HLA allele E*01: 01 is associated with a reduced risk of EBV-related classical Hodgkin lymphoma independently of HLA-A*01/*02. PLoS One.. 2015, 10(8. e0135512

[47] King A, Allan DS, Bowen Met al. . HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells. Eur J Immunol.. 2000, 306): 1623-1631.

[48] Kaiser BK, Barahmand-Pour F, Paulsene Wet al. . Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. J Immunol.. 2005, 174(5): 2878-2884.

[49] Liu X, Song J, Zhang Het al. . Immune checkpoint HLA-E: CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell.. 2023, 41(2): 272-287.e9.

[50] Photos C. HLA-E:CD94–NKG2A Mediates Circulating Tumor Cell Immune Evasion. Cancer Discov. 2023, 13: 806-806.

[51] Middelburg J, Ghaffari S, Schoufour TAWet al. . The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent. Cell Rep.. 2023, 42(12. 113516

[52] Mac Donald A, Guipouy D, Lemieux Wet al. . KLRC1 knockout overcomes HLA-E-mediated inhibition and improves NK cell antitumor activity against solid tumors. Front Immunol.. 2023, 14: 1231916.

[53] Lagana A, Ruan DF, Melnekoff Det al. . Increased HLA-E expression correlates with early relapse in multiple myeloma. Blood.. 2018, 13259.

[54] Abd Hamid M, Wang RZ, Yao Xet al. . Enriched HLA-E and CD94/NKG2A interaction limits antitumor CD8⁺ tumor-infiltrating T lymphocyte responses. Cancer Immunol Res.. 2019, 78): 1293-1306.

[55] Fisher JG, Doyle ADP, Graham LVet al. . XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression. Leukemia.. 2023, 37102036-2049.

[56] Ismael A, Robinette AJ, Huric Let al. . CREB1 promotes expression of immune checkpoint HLA-E leading to immune escape in multiple myeloma. Leukemia.. 2024, 38(8): 1777-1786.

[57] Kamiya T, Seow SV, Wong Det al. . Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. J Clin Invest.. 2019, 129(5): 2094-2106.

[58] Liu B, Zhou H, Tan Let al. . Exploring treatment options in cancer: Tumor treatment strategies. Signal Transduct Target Ther.. 2024, 9(1): 175.

[59] Courau T, Bonnereau J, Chicoteau Jet al. . Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment. J Immunother Cancer.. 2019, 7174.

[60] Myers JA, Schirm D, Bendzick Let al. . Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion. JCI Insight.. 2022, 715. e150079

[61] Cheng W, Zhu N, Wang Jet al. . A role of gut microbiota metabolites in HLA-E and NKG2 blockage immunotherapy against tumors: new insights for clinical application. Front Immunol.. 2024, 15: 1331518.

[62] Li Y, Li Z, Tang Yet al. . Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy. J Immunother Cancer.. 2024, 1210. e009934

[63] Liang YH, Chen KH, Tsai JHet al. . Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cells. J Biomed Sci.. 2021, 28175.

[64] Derré L, Corvaisier M, Charreau Bet al. . Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol.. 2006, 17753100-3107.

[65] Coupel S, Moreau A, Hamidou Met al. . Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation. Blood.. 2007, 10972806-2814.

[66] Pereira BI, Devine OP, Vukmanovic-Stejic Met al. . Senescent cells evade immune clearance via HLA-E-mediated NK and CD8⁺ T cell inhibition. Nat Commun.. 2019, 10(1): 2387.

[67] Sheehy MJ, Meske LM, Emler CAet al. . Allelic T-cell receptor alpha complexes have little or no influence on susceptibility to type 1 diabetes. Hum Immunol.. 1989, 264261-271.

[68] Lin Z, Bashirova AA, Viard Met al. . HLA class I signal peptide polymorphism determines the level of CD94/NKG2-HLA-E-mediated regulation of effector cell responses. Nat Immunol.. 2023, 24(7): 1087-1097.

[69] Jiang H, Yu D, Yang Pet al. . Revealing the transcriptional heterogeneity of organ-specific metastasis in human gastric cancer using single-cell RNA Sequencing. Clin Transl Med.. 2022, 12(2. e730

[70] Sasaki T, Kanaseki T, Shionoya Yet al. . Microenvironmental stresses induce HLA-E/Qa-1 surface expression and thereby reduce CD8⁺ T-cell recognition of stressed cells. Eur J Immunol.. 2016, 464): 929-940.

[71] Hrbac T, Kopkova A, Siegl Fet al. . HLA-E and HLA-F are overexpressed in glioblastoma and HLA-E increased after exposure to ionizing radiation. Cancer Genomics Proteomics.. 2022, 19(2): 151-162.

[72] Yang Y, Liu Z, Wang Het al. . HLA-E binding peptide as a potential therapeutic candidate for high-risk multiple myeloma. Front Oncol.. 2021, 11. 670673

[73] Boujelbene N, Ben Yahia H, Babay Wet al. . HLA-G, HLA-E, and IDO overexpression predicts a worse survival of Tunisian patients with vulvar squamous cell carcinoma. HLA.. 2019, 94(1): 11-24.

[74] Morinaga T, Iwatsuki M, Yamashita Ket al. . Evaluation of HLA-E expression combined with natural killer cell status as a prognostic factor for advanced gastric cancer. Ann Surg Oncol.. 2022, 29(8): 4951-4960.

[75] Benevolo M, Mottolese M, Tremante Eet al. . High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. J Transl Med.. 2011, 9: 184.

[76] Seliger B, Jasinski-Bergner S, Quandt Det al. . HLA-E expression and its clinical relevance in human renal cell carcinoma. Oncotarget.. 2016, 7(41): 67360-67372.

[77] Zhen ZJ, Ling JY, Cai Yet al. . Impact of HLA-E gene polymorphism on HLA-E expression in tumor cells and prognosis in patients with stage III colorectal cancer. Med Oncol.. 2013, 301482.

[78] Feng X, Lai X, Zhou Met al. . Targeting HLA-E in lung cancer: the therapeutic potential of IRF5-engineered M1-macrophage-derived exosomes. Clin Respir J.. 2024, 1812. e70035

[79] Lauterbach N, Wieten L, Popeijus HEet al. . HLA-E regulates NKG2C+ natural killer cell function through presentation of a restricted peptide repertoire. Hum Immunol.. 2015, 768578-586.

[80] Battin C, Kaufmann G, Leitner Jet al. . NKG2A-checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA-E. Immunology.. 2022, 166(4): 507-521.

[81] Matsunami K, Nakai MSet al. . Modulation of the leader peptide sequence of the HLA-E gene up-regulates its expression and down-regulates natural killer cell-mediated swine endothelial cell lysis. Transplantation.. 2002, 73(10): 1582-1589.

[82] Chiossone L, Dumas PY, Vienne Met al. . Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol.. 2018, 18(11): 671-688.

[83] Capuano C, Pighi C, Battella Set al. . Harnessing CD16-mediated NK cell functions to enhance therapeutic efficacy of tumor-targeting mAbs. Cancers.. 2021, 13(10): 2500.

[84] André P, Denis C, Soulas Cet al. . Anti-NKG2A MAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell.. 2018, 17571731-1743.e13.

[85] Lee J, Keam B, Park HRet al. . Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines. J Cancer Res Clin Oncol.. 2023, 149(9): 5705-5715.

[86] Gelman JS, Sironi J, Berezniuk Iet al. . Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib. PLoS One.. 2013, 8(1. e53263

[87] Thangaraj JL, Ahn SY, Jung SHet al. . Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model. Cell Mol Immunol.. 2021, 187): 1652-1661.

[88] Yun HD, Schirm DK, Felices Met al. . Dinaciclib enhances natural killer cell cytotoxicity against acute myelogenous leukemia. Blood Adv.. 2019, 3(16): 2448-2452.

[89] Zhang M, Zhang L, Hei Ret al. . CDK inhibitors in cancer therapy, an overview of recent development. Am J Cancer Res.. 2021, 11(5): 1913-1935

[90] Ruscetti M, Leibold J, Bott MJet al. . NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science.. 2018, 362(6421): 1416-1422.

[91] Fisher JG, Walker CJ, Doyle ADet al. . Selinexor enhances NK cell activation against malignant B cells via downregulation of HLA-E. Front Oncol.. 2021, 11. 785635

[92] Sheffer M, Lowry E, Beelen Net al. . Genome-scale screens identify factors regulating tumor cell responses to natural killer cells. Nat Genet.. 2021, 53(8): 1196-1206.

[93] Hu X, Li J, Fu Met al. . The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther.. 2021, 6(1): 402.

[94] Berenson JR, Martinez D, Safaie Tet al. . Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma. Br J Haematol.. 2023, 2006722-730.

[95] Michelin S, Gallegos CE, Dubner Det al. . Ionizing radiation modulates the surface expression of human leukocyte antigen-G in a human melanoma cell line. Hum Immunol.. 2009, 70(12): 1010-1015.

[96] Battaglia NG, Murphy JD, Uccello TPet al. . Combination of NKG2A and PD-1 blockade improves radiotherapy response in radioresistant tumors. J Immunol.. 2022, 209(3): 629-640.

[97] Tuomela K, Mukherjee D, Ambrose ARet al. . Radiotherapy transiently reduces the sensitivity of cancer cells to lymphocyte cytotoxicity. Proc Natl Acad Sci U S A.. 2022, 119(3. e2111900119

[98] Pagliuca S, Gurnari C, Rubio MTet al. . Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond. Front Immunol.. 2022, 13. 944872

[99] Liu X, Zuo F, Song Jet al. . Immune checkpoints HLA-E: CD94-NKG2A and HLA-C: KIR2DL1 complementarily shield circulating tumor cells from NK-mediated immune surveillance. Cell Discov.. 2024, 101): 16.

[100] Salomé B, Sfakianos JP, Ranti Det al. . NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. Cancer Cell.. 2022, 4091027-1043.e9.

[101] Bexte T, Albinger N, Al Ajami Aet al. . CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells. Nat Commun.. 2024, 15(1): 8439.

[102] Gurung HR, Heidersbach AJ, Darwish Met al. . Systematic discovery of neoepitope-HLA pairs for neoantigens shared among patients and tumor types. Nat Biotechnol.. 2024, 4271107-1117.

[103] Wohlwend J, Nathan A, Shalon Net al. . Deep learning enhances the prediction of HLA class I-presented CD8⁺ T cell epitopes in foreign pathogens. Nat Mach Intell.. 2025, 7(2): 232-243.

[104] Altvater B, Kailayangiri S, Pérez Lanuza LFet al. . HLA-G and HLA-E immune checkpoints are widely expressed in ewing sarcoma but have limited functional impact on the effector functions of antigen-specific CAR T cells. Cancers.. 2021, 13(12): 2857.

[105] Iyer RF, Verweij MC, Nair SSet al. . CD8⁺T cell targeting of tumor antigens presented by HLA-E. Sci Adv. 2024, 1019eadm7515.

[106] Zheng H, Guan X, Meng Xet al. . IFN-γ in ovarian tumor microenvironment upregulates HLA-E expression and predicts a poor prognosis. J Ovarian Res.. 2023, 161229.

[107] Radermacher A, Fehrenz M, Bellin Tet al. . HLA-E and its soluble form as indicators of a sex-specific immune response in patients with oral squamous cell carcinoma. Int J Mol Sci.. 2023, 242316699.

[108] Cascone T, Kar G, Spicer JDet al. . Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II NeoCOAST platform trial. Cancer Discov.. 2023, 13112394-2411.

[109] Herbst RS, Majem M, Barlesi Fet al. . COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer. J Clin Oncol.. 2022, 40(29): 3383-3393.

[110] Patel SP, Alonso-Gordoa T, Banerjee Set al. . Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors. J Immunother Cancer.. 2024, 122. e007340

[111] Fisher JG, Graham LV, Blunt MD. Strategies to disrupt NKG2A: HLA-E interactions for improved anti-cancer immunity. Oncotarget.. 2024, 15: 501-503.

[112] Fisher JG, Doyle ADP, Graham LVet al. . Disruption of the NKG2A: HLA-E immune checkpoint axis to enhance NK cell activation against cancer. Vaccines.. 2022, 10121993.

Funding

Universiti Sains Malaysia(R502-KR-ARU004-0000001081-K134)

RIGHTS & PERMISSIONS

The Author(s), under exclusive licence to the Huazhong University of Science and Technology